Treatment of acute myeloid leukemia

被引：42

作者：

Estey, Elihu H. ^{[1
]}

机构：

[1] Seattle Canc Care Alliance, Seattle, WA USA

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 01期

关键词：

RISK MYELODYSPLASTIC SYNDROME; ACUTE MYELOGENOUS LEUKEMIA; STEM-CELL TRANSPLANTATION; TRANS-RETINOIC ACID; CORE-BINDING-FACTOR; COMPLEX KARYOTYPE; ELDERLY-PATIENTS; DOSE CYTARABINE; CLINICAL-TRIALS; AML;

D O I：

10.3324/haematol.2008.001263

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：10 / 16

页数：7

共 33 条

[31] Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study [J].

Slovak, ML ;

Kopecky, KJ ;

Cassileth, PA ;

Harrington, DH ;

Theil, KS ;

Mohamed, A ;

Paietta, E ;

Willman, CL ;

Head, DR ;

Rowe, JM ;

Forman, SJ ;

Appelbaum, FR .

BLOOD, 2000, 96 (13) :4075-4083

[32]

Thall PF, 2001, HANDBOOK OF STATISTICS IN CLINICAL ONCOLOGY, P411

[33] Accounting for patient heterogeneity in phase II clinical trials [J].

Wathen, J. Kyle ;

Thall, Peter F. ;

Cook, John D. ;

Estey, Elihu H. .

STATISTICS IN MEDICINE, 2008, 27 (15) :2802-2815

← 1 2 3 4 →